Top 10 developments in lupus nephritis.

Abstract

Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.

• Authors: Teresa K Chen, Derek M Fine
• Journal: Current rheumatology reports (Curr Rheumatol Rep) Vol. 15 Issue 9 Pg. 358 (Sep 2013) ISSN: 1534-6307 [Electronic] United States
• PMID: 23893235 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• APOL1 protein, human
• Antibodies, Monoclonal, Murine-Derived
• Apolipoprotein L1
• Apolipoproteins
• Immunosuppressive Agents
• Lipoproteins, HDL
• Rituximab
• Mycophenolic Acid

Topics

• Alleles
• Antibodies, Monoclonal, Murine-Derived (therapeutic use)
• Apolipoprotein L1
• Apolipoproteins (genetics)
• Genetic Predisposition to Disease
• Humans
• Immunosuppressive Agents (therapeutic use)
• Kidney Transplantation
• Lipoproteins, HDL (genetics)
• Lupus Nephritis (drug therapy, genetics, surgery)
• Mycophenolic Acid (analogs & derivatives, therapeutic use)
• Rituximab
• Treatment Outcome